Genetic Engineering of Mesenchymal Stem Cells and Its Application in Human Disease Therapy
Open accessAbstract
The use of stem cells for tissue regeneration and repair is advancing both at the bench and bedside. Stem cells isolated from bone marrow are currently being tested for their therapeutic potential in a variety of clinical conditions including cardiovascular injury, kidney failure, cancer, and neurological and bone disorders. Despite the advantages, stem cell therapy is still limited by low survival, engraftment, and homing to damage area as well as inefficiencies in differentiating into fully functional tissues. Genetic engineering of mesenchymal stem cells is being explored as a means to circumvent some of these problems. This review presents the current understanding of the use of genetically engineered mesenchymal stem cells in human disease therapy with emphasis on genetic modifications aimed to improve survival, homing, angiogenesis, and heart function after myocardial infarction. Advancements in other disease areas are also discussed.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
MSCs overexpressing the survival protein AKT release higher levels of the paracrine factors FGF-2, HGF, IGF-1 and VEGF.
“As an example, MSCs overexpressing the survival protein AKT release higher levels of the paracrine factors FGF-2, HGF, IGF-1 and VEGF [151].”
From Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? (2025) · cites this paper as [151]
Cites
A perivascular origin for mesenchymal stem cells in multiple human organs
Crisan, M., Yap, S., Casteilla, L., Chen, C.-W., Corselli, M., Park, T. S., Andriolo, G., Sun, B., Zheng, B., Zhang, L., et al. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.07.003 · Cited by 3,991 · see citing works
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759 · see citing works
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900 · see citing works
Dash, N. R., Dash, S. N., Routray, P., Mohapatra, S., & Mohapatra, P. C. (2009) · Rejuvenation Research · doi:10.1089/rej.2009.0872 · Cited by 339 · see citing works
Interleukin‐6 is a potent growth factor for ER‐α‐positive human breast cancer
Sasser, A. K., Sullivan, N. J., Studebaker, A. W., Hendey, L. F., Axel, A. E., & Hall, B. M. (2007) · The FASEB Journal · doi:10.1096/fj.07-8832com · Cited by 222 · see citing works
Chen, X., Lin, X., Zhao, J., Shi, W., Zhang, H., Wang, Y., Kan, B., Du, L., Wang, B., Wei, Y., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.3 · Cited by 173 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Saeedi, P., Halabian, R., & Imani Fooladi, A. A. (2019) · Stem Cell Investigation · doi:10.21037/sci.2019.08.11 · Cited by 251 · see citing works
Mesenchymal stem cell secretome for regenerative medicine: Where do we stand?
Trigo, C. M., Rodrigues, J. S., Camões, S. P., Solá, S., & Miranda, J. P. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2024.05.004 · Cited by 205 · see citing works
“Indeed, VEGF promotes angiogenesis and restoring tissues, further highlighting its pivotal role in several tissue injuries, namely in myocardial infarction, wound healing, ischemic stroke, among others [151].”
- Authors
- Hodgkinson, C. P., Gomez, J. A., Mirotsou, M., & Dzau, V. J.
- Affiliations
- Duke Medical Center (US)
- Duke University Medical Center and Mandel Center for Hypertension and Atherosclerosis Research
- Corresponding author
- Dzau, Victor J.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2010-10-22
- Volume
- 21
- Issue
- 11
- Pages
- 1513-1526
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- PMC
- PMC2978545
- OpenAlex
- W2163899718
- Cited by
- 150
- References
- 6
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 7 · 2023: 5 · 2022: 6 · 2021: 10 · 2020: 8 · 2019: 11 · 2018: 13 · 2017: 8 · 2016: 14 · 2015: 7 · 2014: 11 · 2013: 18 · 2012: 14
- FWCI
- 1.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Human Gene Therapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DukeSpace (Duke University) (submittedVersion, cc-by-nc-nd)
- Funders
- National Heart, Lung, and Blood Institute (HL 73219, HL 72010, HL81744, R01HL072010, R01-HL35610, R01HL035610, R01HL073219, R01HL081744)
- Topics
- Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Keywords
- mesenchymal stem cells, genetic engineering, stem cell therapy, bone marrow-derived stem cells, stem cell homing, engraftment, angiogenesis, myocardial infarction, tissue regeneration, cardiovascular damage, renal failure, cancer, neurological disorders, bone disease
- MeSH terms
- Cardiovascular Diseases, Cell Differentiation, Clinical Trials as Topic, Genetic Engineering, Humans, Neoplasms, Nervous System Diseases, Osteogenesis, Bone Marrow Transplantation, Mesenchymal Stem Cell Transplantation, Renal Insufficiency, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
